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By: Amy Martinez, PharmD Candidate
In October 2007, a task force
met with representatives from
the Food and Drug Administration (FDA) and the pharmaceutical industry to make a citizen
petition on the use of over-thecounter (OTC) cough and cold
products for children under age 6
years of age. The petition requested that FDA evaluate the
data on the safety and efficacy of
components of these products
and to issue a statement to the
public explaining that these
products have not been shown to
be safe and effective for the
treatment of cough and cold in
these patients.1,2
The Consumer Healthcare Products Association reported that
approximately 95 million units
of pediatric OTC cough and cold
products are sold annually.2 The
high sales figures are most likely
influenced by the industry’s
heavily advertised reassurance
towards parents on the safety,
effectiveness, as well as recommendations made by physicians.2
Despite these claims, more than
325,000 calls have been placed
to national poison centers regarding children under 6 years of
age being overdosed or having

unexpected toxicities such as hallucinations, agitation, tachyarrhythmias, hypertension, metabolic acidosis and seizures. In a
recent review, 12 deaths were reported related to cough and cold
products.3 The Centers for Disease Control and Prevention
(CDC) estimated that between
2004 and 2005 around 1500 children under the age of 2 years were
treated in emergency departments
because of these products. Additionally, 69 deaths in children
from antihistamines and 54 from
decongestants have been reported
from 1969 to 2006.4 These numbers may not reflect the true incidence of death or adverse events
from cough and cold medications
since adverse effects from OTCs
were not required by FDA to
be reported.
As of December 2007, new reporting requirements for OTC
products went into effect.5 Under
this new public law, the manufacturer, packer, retailer, or distributor of an OTC product must inform FDA MedWatch of any serious adverse event that is reported
to the company.5
The unintentional misuse of these
products may be caused by the co-
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administration of several combination products resulting in duplication of ingredients, or by the
incorrect measurement of doses.
Additionally, different available
concentrations for a particular
product may cause confusion and
lead to under- or overdosing. Due
to the lack of data, some of the
cough and cold products did not
have recommended doses for children under the age of 6 years and
instead, suggested consulting a
pediatrician for dosing. However,
parents may have followed the
1988 dosing advisory of FDA for
administering medications to children (eg, 3/16 of the adult dose for
ages 1 to 2 years; 1/4 for ages 2
to 4 years; and 3/8 for ages 4 to 6
years, etc), which has not been
study as well.6
Most of the cough and cold medications have not undergone clinical studies to prove safety and efficacy in young children, and most
of those that have been studied
were in adolescents. Due to the
difference in physiology and possible differences in pharmacokinetics and pharmacodynamics between these age groups, the data
should not be used interchangeably.4 Additionally, small clinical
trials in children have shown that
some of the components of these
combination products are no more
effective than placebo. Therefore,
these products may put children at
risk of serious adverse effects for
no benefit at all.7 These components include the following:
▪ bromopheniramine
▪ chlorpheniramine
▪ diphenhydramine
▪ guaifenesin
▪ dextromethorphan
▪ phenylephrine
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Some manufacturers of cough
and cold medications voluntarily
withdrew their products tailored
for infants prior to the final decision by FDA.8 They also removed all infant and baby images from packages, added the
statement “do not use to sedate”
on antihistamines and changed
the wording “ask a doctor” to
“do not use” in children less than
2 years of age. Additionally, the
manufacturers state that an effort
would be made to appropriately
study the safety and efficacy of
all cough and cold products in
children.6
In January 2008, FDA issued a
public health advisory on the use
of nonprescription cough and
cold medicine in children, including decongestants, expectorants, antihistamines, and antitussives. FDA recommended
that these products not be used
in infants and children under the
age of 2 years because of the
possibility of serious and potentially life-threatening side effects.9 A review by FDA on the
safe use of OTC cough and cold
products in children between the
ages of 2 and 11 years is cur-
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rently pending. However, FDA
did advise those parents who decide to give these products to their
children 2 years of age and older
to check the active ingredients,
follow the directions on the label,
and to be careful when giving
more than 1 product so as to avoid
avoiding duplication of active ingredients. In addition, FDA also
advised parents to use only the
measuring device that comes with
the product and not to use the
products for sedation.9
Pharmacists and physicians should
now advise parents to treat any
child under the age of 2 years with
nonpharmacologic treatments, and
recommend they do the same for
children between the ages of 2 and
11 years.4,8,9 These treatments
include maintaining hydration,
keeping the child in an upright
position to relieve congestion, and
using saline nose drops, nasal suctioning, or a humidifier. 4,8,9 The
use of acetaminophen (Tylenol®)
is still recommended for pain and/
or fever; however, parents should
be advised to read the label for
proper dosing and use the appropriate measuring device.4

MED•U•WAY
To Care For Patients
*** An MUSC Lecture Series***

The next MED•U•WAY
Conference will focus on
treatment of asthma in adult
patients. The program will be
held on Thursday, April 17,
2008, at 12:00 PM, in 2 West
Amphitheater.

Attendees will receive 1 credit
hour of continuing education, and
lunch is provided.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee.
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Updated Meperidine Use Guidelines
Meperidine is a synthetic opioid
available in intravenous, intramuscular, patient-controlled analgesia
(PCA), subcutaneous, and oral
dosage forms.
Approximately
50% of meperidine is metabolized
during its first pass through the
liver. The active metabolite, normeperidine, has a much longer
half-life than meperidine, 24 to 48
hours versus 3.2 to 3.7 hours, respectively.
Additionally, the
elimination of normeperidine is
highly dependant on renal function.1 Therefore, elderly patients
or patients with renal impairment
are more prone to accumulate normeperidine, which can result in
confusion, mental status changes,
and seizure activity.2
Due to these safety concerns associated with meperidine, several
guidelines have been developed
and implemented for meperidine
use. Joint Commission (JC) supports the Agency for Healthcare
Research and Quality (AHRQ)
guidelines and the American Pain

Society recommendations for
meperidine utilization.3 AHRQ
guidelines state that meperidine
is to be reserved for short
courses in healthy patients with a
documented allergy to other
opioid analgesics.4 The American Pain Society did not provide
specific recommendations for
indication, but did provide guidance on dosage and duration.
According to the recommendations, meperidine should not be
used for greater than 48 hours,
and doses should not exceed 600
mg in a 24-hour period.5,6 The
2002 update to the Beers Criteria
for Potentially Inappropriate
Medication Use in Older Adults
lists meperidine as a safety concern independent of diagnosis or
condition.7 It specifically states
that meperidine, compared with
other opioids, has more disadvantages such as adverse central
nervous system (CNS) effects
and lack of analgesic efficacy in
doses commonly prescribed.

Figure 1. Guidelines for Appropriate Use of Meperidine
Management of acute pain episodes of moderate to severe pain if the patient has one
or more of the following:
▪ Unmanageable adverse reactions (eg, pruritis, hallucinations) to other first-line
opioid agents (eg, morphine, hydromorphone, fentanyl) given at adequate doses
and intervals
▪ Prevention or treatment of drug-induced or blood product-induced rigors (eg,
amphotericin B, muromonab, platelets) and treatment of postanesthesia shivering
▪ Research protocols specifying the use of meperidine under a closely monitored
and safe environment
▪ Neuraxial analgesia for acute pain management administered by the
anesthesiology service
Moderate sedation in gastroenterology procedures for patients less than 65 years of
age, if the patient meets the following criteria:
▪ Patients must have normal renal function
▪ Patients should not have a seizure history or are not taking medications that
lower the seizure threshold

In summary, all guidelines mentioned do not recommend
meperidine as a first line agent for
analgesia. However, if it is used,
it is important to limit its duration
and dose. Therefore, in 2002,
meperidine utilization guidelines
were developed at MUSC to direct
prescribing practices.8
In 2007, a medication use evaluation (MUE) was conducted to determine the adherence to the
MUSC guidelines. The results of
the MUE showed that the majority
of prescribed meperidine doses
did not follow the 2002 MUSC
guidelines. The most common
reason for inappropriate use was
for indication, specifically for
moderate sedation in endoscopic
procedures.
Therefore, the guidelines were
updated to allow for the safe use
of meperidine in patients undergoing gastroenterology procedures.
The use of meperidine will be allowed for moderate sedation in
these procedures for patients less
than 65 years of age who met the
following pre-specified criteria:
have normal renal function and do
not have a seizure history or are
not taking medications that lower
the seizure threshold.
The current guidelines are shown
in Figure 1. Dosing guidelines for
adult patients, contraindications,
and warnings/precautions are also
provided in the guidelines, which
can be found on the MUSC Formulary and Drug Information Resources Web page.
www.formularyproductions.com/musc

Page52
Page

Pharmacy & Therapeutics Update

FORMULARY UPDATE FOR JANUARY 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was February
18, 2008.

in African-American patients. It
is used to improve survival, to
increase the time to hospitalization from heart failure, and to
improve
patient
functional
status.

Additions:
Ambrisentan (Letaris®) is an endothelin receptor blocker indicated for the treatment of pulmonary hypertension. This receptor
mediates vasoconstriction induced
by endothelin; therefore, the >
4000 fold selectivity of ambrisentan allows for selective blockade
of ETa (blocking vasoconstriction) while allowing for ETb to
mediate vasodilation. Ambrisentan is only available to patients
and physicians who have registered with the Letairis® Education
and Access Program (LEAP). A
list of the physicians who are authorized to prescribe will be
posted on the Department of Pharmacy Services Web page.

20 mg isosorbide dinitrate/37.5 mg
hydralazine tablets

5- and 10-mg tablets

Aliskiren (Tekturna®) is approved
for the treatment of hypertension
as monotherapy or in combination
with other antihypertensive drugs.
Aliskiren is a direct renin inhibitor
and decreases plasma renin activity; therefore, it inhibits the conversion of angiotensinogen to angiotensin I. Although aliskiren is
significantly more expensive than
other antihypertensive agents, it
allows another option for treatment using a unique new mechanism of action.
150- and 300-mg tablets

Isosorbide dinitrate/hydralazine
(Bidil®) is approved as an adjunct
to traditional heart failure therapy

Added with Restriction:
Aprotinin (Trasylol®) is indicated for prophylactic use to reduce postoperative blood loss
and the need for blood transfusions in patients undergoing cardiopulmonary bypass during
coronary artery bypass graft surgery. In November 2007, the
marketing of aprotinin was suspended by the manufacturer and
FDA due to a pending detailed
review of preliminary results
from a Canadian study. Letters
were sent to the P&T Committee
in support of the continued use
of aprotinin during the marketing suspension, as the product
was still available at MUSC.
Clinical criteria were developed
for the appropriate use of
aprotinin in both adult and
pediatric patients. Therefore,
aprotinin has been added to the
formulary and restricted per
prescribing service and per clinical criteria. The criteria can be
found on the MUSC Formulary
and Drug Information Resources
Web page.
(www.formularyproductions.com/musc)
100- and 200-mL vials

Change in Restriction:
Conivaptan (Vaprisol®) is indicated for the treatment of euvolemic and hypervolemic hypo-

natremia in hospitalized patients.
The restriction will be updated to
include prescribing restricted to
cardiology attending staff and to
patients in an ICU with hypervolemic hyponatremia that fail
standard therapy [ie, diuretics,
fluid restriction]. A pre-printed
order form has been created and
will need to be used for this indication.
Line Extensions:
▪ Thrombin, topical, bovine origin

(Thrombi JMI®) [5,000-unit kit]
▪ Desmopressin (DDAVP)
[0.1-, 0.2-mg tablets]

Deletions:
▪ Procainamide immediate release
▪
▪
▪
▪
▪
▪
▪

[250-, 375-, 500-mg capsules]
Procainamide extended-release
[500-, 750-, 1000-mg tablets]
Procainamide [50-mg/mL extemporaneous suspension]
Interferon alfa-2A (Roferon-A®)
[3-, 6-, 9-million unit syringes]
Propranolol [20-, 80-mg tablets]
Propranolol long-acting
[120-, 180-mg capsules]
Chloral hydrate (Aquachoral Supprettes®) [325-mg suppositories]
Lepirudin (Refludan®)
[50-mg injection]

Additions to the IV Push Chart
▪ Thiopental
▪ 23.4% sodium chloride
▪ Dantrolene (Dantrium®)
▪ Iodixonal (Visipaque®)
▪ Iohexal (Omnipaque®)
▪ Iopamidol (Isovue®)
▪ Gadopentetate (Magnevist®)
▪ Gadobenate (Multihance®)
New Policy: C152: Use of Sedative and Opioid Reversal Agents
posted on the Clinical Service
Online Policy page
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FORMULARY UPDATE FOR FEBRUARY 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was March 17,
2008.
Addition with Restriction:
Zolendronic acid (Reclast®) is
approved for post menopausal osteoporosis to reduce the incidence
of hip, vertebral, and nonvertebral fractures. Additionally,
it is approved for Paget’s disease
of bone in men and women with
increased alkaline phosphatase
concentrations, experience symptoms from their disease, or are at
risk of complications of their disease. Zolendronic acid is also
available under the trade name
(Zometa®) for the treatment of
hypercalcemia of malignancy and
multiple myeloma and bone metastases of solid tumors. The dose
of Reclast® for postmenopausal
osteoporosis is 5 mg via intravenous infusion (over 15 minutes),
once yearly. Prescribing will be
restricted to the outpatient setting
and proper documentation of approved indications will be necessary for reimbursement.
5-mg/100-mL solution for infusion

Change in Restriction:
The formulary restriction for dexmedetomidine (Precedex®) was
changed to the following:
1) Critical Care - OR setting: prescribing is restricted to attending
physicians or fellows without the
requirement of a pre-printed order
form (formulary effective on February 4, 2008);
2) Critical Care - Outside an OR
setting: prescribing is restricted to

the use of a pre-printed order
form and to attending- or fellowlevel physician approval within
24 hours of order initiation. For
infusions lasting greater than 24
hours, the appropriateness of use
and duration of therapy must be
reassessed within 120 hours of
initiation and justified in the
chart.
The restriction for pantoprazole
injection (Protonix IV®) of gastroerology or hepatology consult
before starting intravenous pantoprazole was removed. Intravenous pantoprazole will still need
to be used per clinical guidelines
and ordered via the pre-printed
order form (in adults).
The clinical criteria include the
following:
▪ Definite or probable evidence
of non-variceal upper gastrointestinal (GI) bleeding when
oral therapy is not clinically
feasible.
▪ Documented bleed and/or
treatment failure while on H2antagonist (famotidine) or sucralfate and oral therapy is not
clinically feasible.
▪ Documented hypersecretory
condition (eg, ZollingerEllison syndrome or idiopathic) and oral therapy is not
clinically feasible.
Restriction Removed:
▪ Fosphenytoin (various)
▪ Ondansetron (Zofran®)
Line Extensions:
▪ Clopidogrel (Plavix®)
[300-mg tablets]

Deletions:
▪ Heparin
[10,000-units/mL injection]
Other Action Items:
▪ Potassium phosphate as an electrolyte replacement has been
removed from the Children’s
Hospital formulary due to potential for adverse effects. Electrolyte replacement for phosphorus in children will be limited to
sodium phosphate. Potassium
must be replaced separately with
potassium chloride.
▪ The following changes will be
made to the enteral formulary
for adult patients. Changes to
the pre-printed order forms will
be made and education will be
provided prior to the switch.
− Nutren 1.0 c with Fiber will
replace Osmolite 1.0 c
− Nutren 1.5 c with Fiber will
replace Jevity 1.5 c
− Nutren 1.0 with replace
Jevity 1 c
− Nutren with Replete will
replace Promote
− Replete with Fiber will
replace Promote with Fiber
− Nutren Renal will replace
Nepro with Carb Steady
− Nutren 2.0 with replace
TwoCal HN
▪ MUSC Guidelines for Treatment
of Community-acquired Pneumonia (CAP) on an Outpatient
Basis were developed by the
Anti-infective
Subcommittee
and approved by the Pharmacy
and Therapeutics Committee.
These will be available via the
clinician order forms Web site.

